118 related articles for article (PubMed ID: 15315798)
1. Procarbazine in haematology: an old drug with a new life?
Massoud M; Armand JP; Ribrag V
Eur J Cancer; 2004 Sep; 40(13):1924-7. PubMed ID: 15315798
[TBL] [Abstract][Full Text] [Related]
2. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
Hehn ST; Miller TP
Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845
[TBL] [Abstract][Full Text] [Related]
3. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture.
Bonadonna G
Cancer Res; 1982 Nov; 42(11):4309-20. PubMed ID: 6181867
[TBL] [Abstract][Full Text] [Related]
5. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
6. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
7. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
Federico M; Luminari S; Iannitto E; Polimeno G; Marcheselli L; Montanini A; La Sala A; Merli F; Stelitano C; Pozzi S; Scalone R; Di Renzo N; Musto P; Baldini L; Cervetti G; Angrilli F; Mazza P; Brugiatelli M; Gobbi PG;
J Clin Oncol; 2009 Feb; 27(5):805-11. PubMed ID: 19124807
[TBL] [Abstract][Full Text] [Related]
8. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
9. Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin's disease.
Raina V; Sharma A; Mohanti BK; Kumar R; Dawar R; Rath GK
Natl Med J India; 2003; 16(4):199-203. PubMed ID: 14606767
[TBL] [Abstract][Full Text] [Related]
10. [Hematologic tumors].
Ogawa M
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1416-21. PubMed ID: 14584273
[TBL] [Abstract][Full Text] [Related]
11. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
12. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
Bonadonna G; Viviani S; Bonfante V; Gianni AM; Valagussa P
Eur J Cancer; 2005 May; 41(7):998-1006. PubMed ID: 15862748
[TBL] [Abstract][Full Text] [Related]
13. [Primary treatment of advanced Hodgkin's disease].
Illés A; Udvardy M; Molnár Z
Orv Hetil; 2005 Jan; 146(5):195-202. PubMed ID: 15773586
[TBL] [Abstract][Full Text] [Related]
14. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma?
Diehl V; Behringer K
Cancer Invest; 2006; 24(4):461-5. PubMed ID: 16777701
[TBL] [Abstract][Full Text] [Related]
15. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?
Diehl V; Behringer K
Cancer Invest; 2006 Nov; 24(7):713-7. PubMed ID: 17118782
[TBL] [Abstract][Full Text] [Related]
16. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
[TBL] [Abstract][Full Text] [Related]
17. [Treating Hodgkin's disease: for whom the more means better?].
Illés A
Magy Onkol; 2004; 48(2):157-61. PubMed ID: 15351812
[TBL] [Abstract][Full Text] [Related]
18. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
19. Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results.
Comella P; Abate G; Fiore M; Di Finizio G; Frezza P; Scoppa G; Anania C; Coucourde F; Zarrilli D
J Chemother; 1989 Jul; 1(4 Suppl):1254-6. PubMed ID: 16312855
[No Abstract] [Full Text] [Related]
20. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]